

1st September, 2023

The Manager,
Listing Compliance Department,
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai- 400051

Symbol: SAKAR

Corporate Office :
406, Silver Oaks Comm. Complex,
Opp. Arun Society, Paldi,
Ahmedabad-380 007. Gujarat, India.
Phone : 079-26584655
Fax : 079-26588054
CIN No. : L24231GJ2004PLC043861
E-mail : info@sakarhealthcare.com
Web : www.sakarhealthcare.com

Dear Sir,

Sub: Outcome of Board Meeting.

Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015 & in furtherance to earlier communication dated 29th August, 2023, we hereby inform you that the Board of Directors of the Company ("Board") was held today i.e. 1st September, 2023, wherein, the Board approved the following:

1. Allotment of Equity Shares.

Allotment of 23,09,910 Equity Shares of the Company having a face value of Rs. 10/- each at an issue price of Rs. 259.75 per Equity Share (including premium of Rs. 249.75 per Equity Share), each fully paid up and in dematerialised form, to Tata Capital Healthcare Fund II, a SEBI Registered Alternate Investment Fund (AIF), being of the Non-Promoter category, by way of a preferential issue on a private placement basis, in accordance with the provisions of Companies Act, 2013 and SEBI (ICDR) Regulations, 2018. With this allotment, the paid-up share capital of the Company is Rs. 21,34,99,100/- divided into 2,13,49,910 Equity Shares of Rs. 10/- each.

2. Appointment of Ms. Vishalakshi Chandramouli, as Additional Director (Non-Executive, Non-Independent Category) w.e.f. 01-09-2023.

She holds qualification degree in MBA (MU), AMP, Harvard Business School Chemical Technologist (ICT, Mumbai) and has Pharmaceutical background. She has over 30 years of experience across Pharmaceutical R&D operations. She is also a part of the Leadership Team and governance committee of the Healthcare Industry body, NATHEALTH. The Board considers that her association with Sakar would be of immense benefit to the Company and her experience and expertise in Pharmaceutical industries will help the company.

In accordance with Regulation 30 of Listing Regulations, the necessary disclosures are enclosed herewith as Annexure A & Annexure B respectively.

We will approach you in due course of time for Listing Application in terms of SEBI Listing Regulations.

The Board Meeting commenced at 10 a.m. and concluded at 11 a.m.

Kindly take same on your record.

Thanking you,

Yours faithfully,

FOR SAKAR HEALTHCARE LIMITED


BHARAT SONI
COMPANY SECRETARY
& COMPLIANCE OFFICER



Sr. No.	Particulars of disclosure	Disclosure														
1.	Types of securities issued	Equity shares having face value of ₹10/- per equity share ("Equity Shares").														
2.	Type of issuance/allotment	Preferential Issue/allotment														
3.	Total number of securities issued	23,09,910 Equity Shares at an issue price of Rs.259.75 per share														
4.	Details to be furnished in case of preferential issue															
	a. Name of the investors	TATA CAPITAL HEALTHCARE FUND II, a SEBI Registered Alternate Investment Fund (AIF), acting through its trustee Tata Trustee Company Private Limited.														
	b. Post allotment of securities outcome of the subscription, issue price /allotted price (in case of convertibles), number of investors	<p>Outcome of allotment:</p> <table border="1"> <thead> <tr> <th rowspan="2">Investor</th> <th colspan="2">Pre-Issue equity shareholding</th> <th colspan="2">Post-issue equity shareholding</th> </tr> <tr> <th>No.</th> <th>%</th> <th>No.</th> <th>%</th> </tr> </thead> <tbody> <tr> <td>Tata Capital Healthcare Fund II(acting through its trustee Tata Trustee Company Private Limited)</td> <td>NIL</td> <td>NIL</td> <td>23,09,910</td> <td>10.82%</td> </tr> </tbody> </table> <p>Issue Price: Equity Shares allotted to the aforementioned allottee at a price of Rs. 259.75 each.</p> <p>Number of Investors: Allotment is made to one investor only as already disclosed</p>	Investor	Pre-Issue equity shareholding		Post-issue equity shareholding		No.	%	No.	%	Tata Capital Healthcare Fund II(acting through its trustee Tata Trustee Company Private Limited)	NIL	NIL	23,09,910	10.82%
Investor	Pre-Issue equity shareholding			Post-issue equity shareholding												
	No.	%	No.	%												
Tata Capital Healthcare Fund II(acting through its trustee Tata Trustee Company Private Limited)	NIL	NIL	23,09,910	10.82%												
	In case of convertibles - intimation on conversion of securities or on lapse of the tenure of the instrument	Not Applicable														
5.	Any cancellation or termination of proposal for issuance of securities Including reasons thereof	Not Applicable														
6.	Lock in	The Equity Shares is subject to 'lock-in' as prescribed under the applicable provisions of the SEBI ICDR Regulations.														

For SAKAR HEALTHCARE LIMITED


Bharat Soni
 BHARAT SONI
 COMPANY SECRETARY &
 COMPLIANCE OFFICER



ANNEXURE B**BRIEF PROFILE OF DIRECTOR**

Name of Director	Ms. Visalakshi Chandramouli
Qualification of Director	MBA (MU), AMP, Harvard Business School Chemical Technologist (ICT, Mumbai)
Experience/Expertise in Specific Functional Areas of Director	Visalakshi has over 30 years of experience across Pharmaceutical R&D operations. She is also a part of the Leadership Team and governance committee of the Healthcare Industry body, NATHEALTH.
Date of Appointment	01-09-2023
Reason for change / Terms of Appointment	Appointment as Additional Director (Non Executive Non Independent)
Shareholding of Director in the Company	NIL
Relationship between Directors	Not Related

For SAKAR HEALTHCARE LIMITED


BHARAT SONI
COMPANY SECRETARY &
COMPLIANCE OFFICER